• Panobinostat Targets MLL-Rearranged ALL In Vivo

  2026-10-09

  A 2018 Leukemia study showed that the HDAC inhibitor panobinostat produced substantial anti-leukaemic effects in xenograft models of MLL-rearranged acute lymphoblastic leukaemia. Molecular analyses linked this activity to suppression of the RNF20/RNF40/WAC pathway and reduced histone H2B ubiquitination, identifying a potentially important epigenetic vulnerability while remaining within a preclinical evidence base.

• Gly-Gly-Phe-Gly (GGFG): Evidence and Limits

  2026-10-09

  Gly-Gly-Phe-Gly, also called the GGFG peptide, is a four-residue linker described for drug conjugation, peptide engineering, and biomaterial construction. Its documented role is structural and modular, while the supplied leukemia study provides evidence about panobinostat rather than GGFG itself.

• Epoxomicin: Evidence, Uses, and Limits

  2026-10-08

  This scientific overview explains what Epoxomicin can reveal about proteasome-dependent protein quality control, how strong the available evidence is, and where interpretation should stop. It distinguishes supplier-reported pharmacology from findings in a primary mammalian cell study of UBR1 and UBR2, with emphasis on mechanism, evidence quality, scope, and limitations rather than experimental instructions.

• HyperFluor 488 Goat Anti-Rabbit IgG Overview

  2026-10-08

  A source-limited overview of APExBIO’s listed goat anti-rabbit IgG (H+L) fluorescent antibody conjugate. No matched paper evidence is available to verify performance or application compatibility.

• Light-Controlled RNA Release for Gene Therapy

  2026-10-07

  A 2026 Trends in Biotechnology study describes a rationally designed light-inducible RNA-releasing protein (LIRP) that regulates therapeutic gene expression at the level of translation. Evidence from mammalian cells and mouse disease models suggests that LIRP can provide temporally controllable transgene activity across liver-, skin-, and eye-relevant applications, although clinical translation remains untested.

• B3465: α2-Adrenergic Receptor Evidence

  2026-10-07

  5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine is examined as an α2-adrenergic receptor agonist through the lens of immune-context-dependent evidence. This article distinguishes direct tumor-cell effects from CD8+ T-cell and TCR-associated mechanisms while defining the study’s translational limits.

• Bifendate in Acute Liver Injury: Multiomics Evidence

  2026-10-06

  Talifu et al. used co-expression networks, transcriptomics, and proteomics to compare how bifendate and muaddil sapra affect molecular modules in a preclinical acute liver injury model. The study supports a systems-level view of DDB-associated responses, while its model and association-based analyses limit direct conclusions about human efficacy or clinical mechanism.

• HOBt in Medicinal Chemistry: Evidence and Limits

  2026-10-05

  A source-grounded overview of HOBt in amide bond formation, using a glucagon receptor antagonist study to distinguish reagent utility from downstream biological evidence, while examining peptide synthesis applications, evidence strength, and research limitations.

• Cy5 Amine (Non-Sulfonated): Product Overview

  2026-10-05

  Cy5 amine (non-sulfonated), SKU A8143, is a supplier-described amine-functionalized cyanine dye for research labeling applications. No matched paper evidence was provided, so its stated specifications and application scope should not be treated as independently validated performance.

• HOBt in Peptide Coupling: Evidence and Limits

  2026-10-03

  HOBt is widely associated with amide bond formation and minimizing epimerization in peptides. This overview examines its conceptual chemistry context, its documented use in a 2015 glucagon receptor antagonist study, and the limits of inferring reagent performance from medicinal-chemistry outcomes.

• Mianserin HCl: 5-HT2 Assay Workflows

  2026-10-02

  Mianserin HCl supports controlled studies of 5-HT2 receptor signaling, neuronal phenotypes, cyclodextrin-enabled cytotoxicity, and antipathogenic activity. This practical guide connects the compound’s receptor pharmacology with reproducible dosing, assay design, and troubleshooting strategies.

• 3-Deazaadenosine for Methylation & Viral Models

  2026-10-01

  3-Deazaadenosine is a mechanistically useful S-adenosylhomocysteine hydrolase inhibitor for separating methylation-dependent effects from gene-specific perturbations. This workflow-focused guide covers inflammatory cell models, preclinical antiviral research, formulation, assay design, and troubleshooting.

• Propranolol Research Workflows and Troubleshooting

  2026-10-01

  Build reproducible Propranolol experiments spanning cardiovascular regulation, emotional memory modulation, essential tremor research, and metabolic assays. This guide combines formulation controls, functional endpoints, dose-screening logic, and troubleshooting for a non-selective β-adrenergic receptor blocker.

• DDM for Dynamic Membrane Protein Structures

  2026-09-30

  Explore how n-Dodecyl-β-D-maltoside (DDM) can support membrane protein structural studies without disguising conformational heterogeneity. This guide connects detergent chemistry with recent full-length αvβ3 integrin cryo-EM findings and practical assay design.

• Transcription Condensates and Genome Stability

  2026-09-30

  Marmolejo et al. identify a cell-cycle timer that forms transcription condensates at histone locus bodies during the G1/S transition and removes them in mid-S phase through ATR-CHK1 signaling. The study connects condensate resolution with linker histone H1.1 control and genome protection, offering a mechanistic framework for understanding replication-transcription coordination.

7947 records 1/530 page Next 12345 下5页 Last page